Clinical trials: Carcinoma of Prostate (Disorder)
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC)
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig…
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
- Trial name
- NCT05652686
- Testing
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel.
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- Phanes Therapeutics
Prostate Cancer, Benign Prostatic Hyperplasia
Application of DWI in Diagnosis of Prostate Cancer
This study compared the performance of different models of multiple b-value DWI in diagnosing prostate cancer.
- Trial name
- NCT04962269
- Testing
- MRI
- Volunteers
- 103 people
- Sponsor
- Peking University Third Hospital
Prostate Cancer
Early Prostate Cancer: Predicting Treatment Response
This study will replicate/validate the risk prediction model developed for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study in a more diverse patient population to assess generalizability of the…
- Trial name
- NCT03770351
- Where
- 5 sites in United States
- Volunteers
- 693 people
- Sponsor
- University of California, Irvine
Prostatic Neoplasms, Castration-Resistant
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate if the anti-tumor activity of JNJ-809 combined with apalutamide is improved compared with apalutamide alone for subjects with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT02906605
- Testing
- JNJ-809, Apalutamide
- Where
- United States
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer
Patients with primary low and intermediate risk prostate cancer (PCa) for whom radical prostatectomy are indicated, will be invited to participate to the present study.
- Trial name
- NCT05073653
- Testing
- 68Ga-PSMA PET/CT, 68Ga-GRP PET/CT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xiangya Hospital of Central South University
Prostate Cancer
A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.
The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer.
- Trial name
- NCT06052683
- Testing
- Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant, Stereotactic Body Radiation Therapy to the prostate
- Where
- Canada
- Volunteers
- 208 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
Primary Objective: To evaluate the safety and tolerability of PET imaging following a single intravenous infusion of [⁶⁸Ga]Ga-ELI421 injection in patients with prostate cancer.
- Trial name
- NCT07689656
- Testing
- [68Ga]Ga-ELI421 injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Adenocarcinoma of the Prostate
Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate
The purpose of this study is to determine the feasibility and late toxicity of dose escalated radiation therapy to the pelvic lymph nodes and prostate and seminal vesicles in the treatment of high risk prostate cancer.
- Trial name
- NCT00915122
- Testing
- Dose Escalated IMRT
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- University Health Network, Toronto
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen [PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance.
- Trial name
- NCT02326805
- Testing
- Laboratory Biomarker Analysis, Rilimogene Galvacirepvec
- Where
- 7 sites in United States
- Volunteers
- 154 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
This is a non-randomized multi-center Phase 1b/2a dose escalation and dose expansion study testing DKN-01 as monotherapy or in combination with docetaxel in metastatic castration-resistant prostate cancer.
- Trial name
- NCT03837353
- Testing
- DKN-01, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started…
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06931340
- Testing
- Androgen Therapy, Apalutamide, Docetaxel
- Where
- 214 sites in United States
- Volunteers
- 1,260 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
PRostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation Procedures
The aim of this study is to assess the efficacy of MRI-targeted biopsy compared to standard of care systematic TRUS guided biopsy in the detection of clinically significant and clinically insignificant prostate cancer in men…
- Trial name
- PRECISE (NCT02936258)
- Testing
- Standard of Care, MRI, MRI Targeted Biopsy
- Where
- 5 sites in Canada
- Volunteers
- 450 people
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer
Focal Therapy Using HIFU for Localised Prostate Cancer
To evaluate the rate of patients without cancer detected by biopsies performed six months after hemi-ablation with high intensity focused ultrasound (HIFU) (Ablatherm ®).
- Trial name
- NCT02016040
- Testing
- High Intensity Focused Ultrasound
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Jewish General Hospital
Prostate Cancer
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
The study was a three-arm, active-control, multi-centre, parallel group study.
- Trial name
- NCT00295750
- Testing
- Degarelix, Leuprolide 7.5 mg
- Where
- 35 sites in United States, Canada and 10 more
- Volunteers
- 620 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA <0.70 ng/ml)…
- Trial name
- PROPER2 (NCT04858880)
- Testing
- Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
- Where
- 3 sites in Sweden
- Volunteers
- 374 people
- Sponsor
- Lund University Hospital
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
This research trial studies molecular characterization of circulating tumor cells (CTCs) and circulating tumor (ct) deoxyribonucleic acid (DNA) in blood and plasma samples from patients with prostate cancer that has spread to…
- Trial name
- NCT02370355
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Prostate Cancer
Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences
There are substantial uncertainties with contemporary seed placement techniques in prostate brachytherapy, particularly with the impact of seed movement after an implant due to edema and migration of seeds in the prostate and…
- Trial name
- NCT01355185
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- AHS Cancer Control Alberta
Prostatic Neoplasms, Low Grade Prostate Cancer
Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
The purpose of this study is to determine whether marine omega-3 fatty acids and 5-alpha-reductase inhibitor are effective in the progression of prostate cancer for low-risk prostate cancer patients.
- Trial name
- NCT01653925
- Testing
- Dietary intervention first, Drug (Dutasteride) intervention first
- Where
- 2 sites in Canada
- Volunteers
- 120 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer
Many patients with localized prostate cancer choose radiotherapy for treatment. Recent improvements in technology have lead to better outcomes with less side effects and better disease control rates by allowing high doses of…
- Trial name
- NCT00129025
- Testing
- Hypofractionated radiotherapy
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Alberta Health services
Prostate Cancer, PD-L1
Immune Profiling After HDR in Local Relapsed Prostate Cancer
Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer until now fails to respond to classical IO, like PD-1 and CTLA-4 inhibitors.
- Trial name
- PRIMUS (NCT04247217)
- Testing
- HDR salvage brachytherapy
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Maastricht Radiation Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.